- Innovative technique aims to bypass the most difficult barrier in brain cancer treatment
Author Archive: AZBioPEERS Team
CAMI receives $4M financial investment from Maricopa County
TUCSON, Arizona — The University of Arizona Health Sciences Center for Advanced Molecular and Immunological Therapies received a strong vote of support from the Maricopa County Board of Supervisors with the June 28 approval of $4 million in funding for the life sciences innovation hub being developed on the Phoenix Bioscience Core in downtown Phoenix.Continue reading
HonorHealth Research Institute makes key contributions to cancer breakthrough for women
SCOTTSDALE, Ariz.– HonorHealth Research Institute played a key role in what is being described as a substantial improvement in the treatment of primary advanced or first recurrent endometrial cancer, the nation’s most common gynecological malignancy.Continue reading
HonorHealth Research Institute is Arizona’s first to adopt new radiation protection technology in treatment of heart disease
SCOTTSDALE, Ariz.– HonorHealth Research Institute announced today that it is among the first healthcare providers in the U.S., and the first in Arizona, to use an advanced radiation protection system as part of the diagnosis and treatment of heart disease.Continue reading
Startup Metfora to advance development of AI-enabled diagnostic technology
TUCSON, AZ – University of Arizona startup Metfora, LLC has announced that it is the recipient of a Small Business Innovation Research (SBIR) Phase l Award from the National Science Foundation to pursue the detection of chronic diseases via multiplex analysis of circulating metabolites. The company will receive a one-year grant of $255,706 to expand a pioneering diagnostic technology originally developed at the UArizona College of Medicine – Tucson.Continue reading
Researchers detail changes in the blood-brain barrier related to Alzheimer’s disease
The brain tissue grows and accumulates abnormal inflammatory signals
RESI Boston June 2023
Life Science Nation is hosting a RESI conference which will be hybrid, June 5-7th. It will take place onsite on Monday June 5th at the Westin Copley Place from 8am – 5pm Eastern Time, and digitally on the 6th and 7th on the Partnering Platform. LSN is offering Arizona Bioindustry Association (AZBio) members a discounted registration for their early-stage startupsContinue reading
Aqualung Therapeutics Concludes ALT-100 Antibody (mAb) Dosing in Its P1a Study with no Reported SAE’s. Will Engage FDA for Clearance of the P2a PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients
TUCSON, AZ / ACESSWIRE / January 31, 2023 / Aqualung Therapeutics, an early stage immunotherapeutics company with a novel anti-inflammatory and anti-fibrotic therapeutic platform for life-threatening unchecked inflammation/fibrosis, today announced that it has engaged Novotech, a leading Asia Pacific centered, full-service contract research organization (“CRO”) in the Asia-Pacific, United States and Europe, for its upcoming Phase 2a PUERTA clinical trial utilizing the humanized ALT-100 mAb. Aqualung currently plans to initiate its Phase 2a clinical trial in Australia starting in Q2 2023. The study will enroll moderate/severe ARDS subjects in hospital locations in Australia as well at multiple sites in the United States.Continue reading
The MedTech Conference 2023: Call for Sessions 2023
Submit session ideas focusing on the latest trends, advancements and critical issues in our field.Continue reading
HTG Molecular Diagnostics Announces the Next Event in its RNA Profiling in Drug Discovery KOL Webcast Series
TUCSON, Ariz., Dec. 09, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced it will host its next HTG Therapeutics key opinion leader (KOL) webinar: “The Role of RNA Profiling in Drug Discovery and Analysis”, on Tuesday, December 13, 2022 at 11:00 am Eastern Standard Time.Continue reading